Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infections
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy.
- Trial name
- ESPRIT (NCT00004978)
- Testing
- Recombinant interleukin-2 (rIL-2)
- Where
- 248 sites in United States, Argentina and 23 more
- Volunteers
- 4,150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
This is a Phase 2b/3, multi-center, two part study, designed to evaluate the efficacy, safety, and tolerability of PRO 140 in conjunction with existing ART (failing regimen) for one week and Optimized Background Therapy (OBT) for…
- Trial name
- PRO140 (NCT02483078)
- Testing
- PRO 140, Optimized Background Regimen
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 52 people
- Sponsor
- CytoDyn, Inc.
HIV
Representations and Acceptability of HIV Therapeutic Vaccine in a Cohort of HIV-1 Infected Outpatients Followed at Hospital
The main objective of the study is to assess the acceptability of a future therapeutic vaccine against HIV in patients living with HIV-1.
- Trial name
- RAVVIH (NCT02077101)
- Testing
- Questionnaire, Interview
- Where
- 3 sites in France
- Volunteers
- 220 people
- Sponsor
- Hopital Foch
HIV
Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients
Triple antiretroviral regimens have greatly improved the prognosis of patients living with HIV (PLHIV). Patients virologically controlled and having a good immune restoration can have a life expectancy close or equal to that of…
- Trial name
- MONCAY (NCT02596334)
- Testing
- dolutegravir 50mg +abacavir 600mg +lamivudine 300mg, dolutegravir
- Where
- 9 sites in France
- Volunteers
- 158 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
HIV Infections
Observational Study of HIV Infected Women Previously Enrolled in Other Microbicide Trials
A new approach to HIV prevention currently being studied includes the use of topical microbicides and orally administered anti-HIV drugs.
- Trial name
- NCT00514098
- Where
- 18 sites in Malawi, South Africa and 3 more
- Volunteers
- 479 people
- Sponsor
- Microbicide Trials Network
Chronic HIV Infections
Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir
HIV replication can be effectively suppressed and acquired immunodeficiency syndrome(AIDS) can be prevented with highly active antiretroviral therapy (HAART).
- Trial name
- CHARTER (NCT02513901)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Tang-Du Hospital
HIV I Infection, Cardiovascular Risk Factor
Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV
This research application will explore the impact of the Non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine in the setting of established Nucleoside reverse transcriptase inhibitors (NRTIs) backbone [Tenofovir…
- Conditions
- HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders
- Trial name
- NCT04820933
- Testing
- Doravirine 100 Mg
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Texas Southwestern Medical Center
HIV Infections
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults
The purpose of this study was to evaluate the efficacy of GSK3640254 + DTG relative to lamivudine (3TC) + DTG in treatment-naïve adult participants living with human immunodeficiency virus (HIV)-1.
- Trial name
- DYNAMIC (NCT04900038)
- Testing
- GSK3640254, Dolutegravir, Lamivudine capsules
- Where
- 44 sites in United States, Argentina and 8 more
- Volunteers
- 85 people
- Sponsor
- ViiV Healthcare
HIV-1-infection
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
Understanding how co-morbidities in persons with HIV (PWH) such as substance use affect risk-taking, decision-making, and other cognitive behaviors is important given implications for everyday functioning and transmission risk.
- Trial name
- NCT04883255
- Testing
- 10 mg Δ9-tetrahydrocannabinol (THC), 600 mg cannabidiol (CBD)
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
HIV-1 Infection
Rosuvastatin to Decrease Residual Immune Activation in HIV Infection
Participating countries: France Objectives Principal objective To evaluate, in HIV-1 infected patients receiving effective antiretroviral therapy, the effect of the addition of Rosuvastatin (dose of 20mg/day) for 3 months, on CD8…
- Trial name
- CESAR (NCT01874743)
- Testing
- Rosuvastatin 20 mg/day
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
HIV Infection
Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults
The purpose of this study is to determine the safety of an immune response to an investigational HIV vaccine, ADMVA, at three different dosage levels, in adults who are not infected with HIV
- Trial name
- NCT00252148
- Testing
- ADMVA
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV Infections
A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3
To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness.
- Trial name
- NCT00000755
- Testing
- rgp120/HIV-1MN, Zidovudine
- Where
- 10 sites in United States
- Volunteers
- 168 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunodeficiency Virus Type 1, Human
A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects
The purpose of this study is to demonstrate non-inferiority in efficacy of a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus Darunavir/Cobicistat (DRV/COBI) FDC…
- Trial name
- NCT02431247
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC
- Where
- 80 sites in United States, Belgium and 8 more
- Volunteers
- 725 people
- Sponsor
- Janssen Sciences Ireland UC
HIV Infections, HIV Seronegativity
A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine
The purpose of this study is to see if it is safe to give an HIV vaccine (vCP205) to volunteers who received an HIV vaccine at least 2 years ago, and to study how the immune system responds to this vaccine.
- Trial name
- NCT00001136
- Testing
- ALVAC-HIV MN120TMG (vCP205)
- Where
- 6 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
This is a phase 2 study to evaluate the safety and tolerability of combination therapy with Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and explore the potential of viral suppression…
- Trial name
- NCT04819347
- Testing
- Albuvirtide, 3BNC117
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Frontier Biotechnologies Inc.
HIV Infection
A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine
The purpose of this study is to compare the body fat distribution in Human Immunodeficiency Virus-1 (HIV-1) infected patients receiving, since the beginning and for at least two years, an antiretroviral therapy based on efavirenz…
- Trial name
- LYNX (NCT01159743)
- Where
- 26 sites in Spain
- Volunteers
- 346 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infection, Human Immunodeficiency Virus
Evaluation of the Safety of a Polyvalent Virus in Healthy Adults
This is a research study to evaluate the safety of a vaccine to protect people from HIV infection. Human Immunodeficiency Virus (HIV) is the cause of AIDS (Acquired Immune Deficiency Syndrome).
- Trial name
- NCT00187044
- Testing
- PolyEnv1 vaccine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
HIV Infections
A Study of the Long-Term Outcomes of HIV-Positive Patients
The purpose of this study is to collect information about life spans and HIV-related illnesses in multiple groups of HIV-positive patients with varying anti-HIV treatment experience, including no treatment at all.
- Trial name
- NCT00000932
- Where
- 91 sites in United States
- Volunteers
- 3,669 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV Infections
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Since the first line antiretroviral (ARV) treatment is now largely accessible in the Sub-Saharian Africa countries, documentation of virological failure, drug resistance patterns and second line treatment evaluation are still to…
- Trial name
- 2LADY (NCT00928187)
- Testing
- emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line), abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line), emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
- Where
- 3 sites in Burkina Faso, Cameroon and 1 more
- Volunteers
- 454 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1-infection
PrEPsmart 2-1-1 Pilot
This is a pilot study to assess the feasibility, acceptability, and preliminary effectiveness of pre-exposure prophylaxis (PrEP)smart among cisgender sexual minority males (SMM) taking on-demand PrEP over a 6-month period.
- Trial name
- NCT06631365
- Testing
- PrEPsmart mobile app, Truvada
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Public Health Foundation Enterprises, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.